
https://www.science.org/content/blog-post/dr-lowe-i-have-your-hypothesis-line-two
# Dr. Lowe? I Have Your Hypothesis on Line Two (January 2004)

## 1. SUMMARY

This is a personal reflection from a medicinal chemist in a pharmaceutical/biotechnology setting, written as a blog-style diary entry in January 2004. The author describes having their experimental work paused for several weeks due to a higher-priority drug discovery program that occupied critical instrumentation and personnel. The samples are now moving back to the top of the queue, with results expected within days.

The author expresses that these upcoming experiments should provide definitive answers about their hypothesis—either confirming or refuting it with minimal ambiguity. The tone captures the tension and uncertainty inherent in scientific research, emphasizing how experimental results can make or break an idea. This appears to be part of Derek Lowe's "In the Pipeline" blog series, where he documented real-world experiences in drug discovery research.

## 2. HISTORY

This particular entry is one of many in Derek Lowe's influential "In the Pipeline" blog, which began in 2002 and became one of the most widely-read chronicles of pharmaceutical research. The blog provided an insider's view of drug discovery, discussing both the scientific and practical challenges of the field. Over the following two decades, the blog evolved into a highly respected source of commentary on pharmaceutical and biotech industry developments, eventually moving to Science Translational Medicine and later to various platforms including his current standalone site.

In terms of broader context around 2004, the pharmaceutical industry continued to face productivity challenges, with R&D costs escalating while drug approval rates remained relatively flat. The following years would see continued consolidation in the industry, increased focus on biologics and targeted therapies, and growing attention to translational medicine as a field attempting to bridge the gap between basic research and clinical applications. The kind of resource constraints and priority-setting described in this post remained characteristic of industrial drug discovery throughout this period.

## 3. PREDICTIONS

There are no specific scientific or technological predictions in this article—it's a personal account of the research process rather than a commentary making forward-looking statements.

## 4. INTEREST

Rating: **3/10**

This is primarily a personal anecdote about the realities of laboratory work rather than a substantive analysis of biotechnology developments or scientific breakthroughs. While it authentically captures the experience of drug discovery research, it lacks the broader industry context, data, or insights that would make it more informative from a biotechnology perspective.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20040122-dr-lowe-i-have-your-hypothesis-line-two.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_